SK7382000A3 - Substituted 2-(2,6-dioxo-3-fluoropiperidin-3-yl)-isoindolines, pharmaceutical composition containing the same and their use - Google Patents

Substituted 2-(2,6-dioxo-3-fluoropiperidin-3-yl)-isoindolines, pharmaceutical composition containing the same and their use Download PDF

Info

Publication number
SK7382000A3
SK7382000A3 SK738-2000A SK7382000A SK7382000A3 SK 7382000 A3 SK7382000 A3 SK 7382000A3 SK 7382000 A SK7382000 A SK 7382000A SK 7382000 A3 SK7382000 A3 SK 7382000A3
Authority
SK
Slovakia
Prior art keywords
dioxo
fluoropiperidin
isoindoline
substituted
oxo
Prior art date
Application number
SK738-2000A
Other languages
English (en)
Slovak (sk)
Inventor
George W Muller
David I Stirling
Roger Shen-Chu Chen
Hon-Wah Man
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/976,140 external-priority patent/US5874448A/en
Priority claimed from US09/042,274 external-priority patent/US5955476A/en
Application filed by Celgene Corp filed Critical Celgene Corp
Publication of SK7382000A3 publication Critical patent/SK7382000A3/sk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/08—Antibacterial agents for leprosy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
SK738-2000A 1997-11-18 1998-11-17 Substituted 2-(2,6-dioxo-3-fluoropiperidin-3-yl)-isoindolines, pharmaceutical composition containing the same and their use SK7382000A3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/976,140 US5874448A (en) 1997-11-18 1997-11-18 Substituted 2-(2,6 dioxo-3-fluoropiperidin-3-yl)-isoindolines and method of reducing TNFα levels
US09/042,274 US5955476A (en) 1997-11-18 1998-03-13 Substituted 2-(2,6-dioxo-3-fluoropiperidin-3-yl)-isoindolines and method of reducing inflammatory cytokine levels
PCT/US1998/024453 WO1999046258A1 (en) 1998-03-13 1998-11-17 SUBSTITUTED 2-(2,6-DIOXO-3-FLUOROPIPERIDIN-3-YL)-ISOINDOLINES AND THEIR USE TO REDUCE TNFα LEVELS

Publications (1)

Publication Number Publication Date
SK7382000A3 true SK7382000A3 (en) 2000-12-11

Family

ID=26719049

Family Applications (1)

Application Number Title Priority Date Filing Date
SK738-2000A SK7382000A3 (en) 1997-11-18 1998-11-17 Substituted 2-(2,6-dioxo-3-fluoropiperidin-3-yl)-isoindolines, pharmaceutical composition containing the same and their use

Country Status (14)

Country Link
EP (3) EP1308444B1 (de)
AT (2) ATE327228T1 (de)
AU (1) AU752958B2 (de)
CY (1) CY1106100T1 (de)
CZ (1) CZ299808B6 (de)
DE (2) DE69811962T2 (de)
DK (1) DK1308444T3 (de)
ES (2) ES2262753T3 (de)
FI (1) FI20001192L (de)
HK (1) HK1054381B (de)
NO (1) NO318737B1 (de)
PT (1) PT1308444E (de)
SI (1) SI1308444T1 (de)
SK (1) SK7382000A3 (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR200101500T2 (tr) * 1998-03-16 2002-06-21 Celgene Corporation 2-(2,6-dioksopiperidin-3-il)izoindolin türevleri, bunların hazırlanması ve enflamatuarn sitokinlerin inhibitörleri olarak kullanımı.
US20050100529A1 (en) * 2003-11-06 2005-05-12 Zeldis Jerome B. Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of asbestos-related diseases and disorders

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1531492A (en) * 1991-02-14 1992-09-15 Rockefeller University, The Method for controlling abnormal concentration tnf alpha in human tissues
US5629327A (en) * 1993-03-01 1997-05-13 Childrens Hospital Medical Center Corp. Methods and compositions for inhibition of angiogenesis
US5463063A (en) * 1993-07-02 1995-10-31 Celgene Corporation Ring closure of N-phthaloylglutamines
DE4422237A1 (de) * 1994-06-24 1996-01-04 Gruenenthal Gmbh Verwendung von Lactamverbindungen als pharmazeutische Wirkstoffe
DE19613976C1 (de) * 1996-04-09 1997-11-20 Gruenenthal Gmbh Thalidomid-Prodrugs mit immunmodulatorischer Wirkung
DE69740140D1 (de) * 1996-07-24 2011-04-14 Celgene Corp Substituierte 2-(2,6-Dioxopiperidin-3-yl)-phthalimide und Oxoisoindoline und Verfahren zur Verringerung der TNF-Alpha-Stufen
HU228769B1 (en) * 1996-07-24 2013-05-28 Celgene Corp Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and their use for production of pharmaceutical compositions for mammals to reduce the level of tnf-alpha
US5635517B1 (en) * 1996-07-24 1999-06-29 Celgene Corp Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines

Also Published As

Publication number Publication date
DE69811962T2 (de) 2003-08-28
HK1054381A1 (en) 2003-11-28
CZ20001822A3 (cs) 2000-11-15
ES2192342T3 (es) 2003-10-01
HK1054381B (en) 2006-10-13
EP1062214B1 (de) 2003-03-05
FI20001192A7 (fi) 2000-07-14
AU1413899A (en) 1999-09-27
EP1710242A1 (de) 2006-10-11
PT1308444E (pt) 2006-08-31
ATE233753T1 (de) 2003-03-15
ES2262753T3 (es) 2006-12-01
NO318737B1 (no) 2005-05-02
EP1308444A1 (de) 2003-05-07
SI1308444T1 (sl) 2007-04-30
DE69834668D1 (de) 2006-06-29
DE69811962D1 (de) 2003-04-10
NO20002529D0 (no) 2000-05-16
AU752958B2 (en) 2002-10-03
ATE327228T1 (de) 2006-06-15
FI20001192L (fi) 2000-07-14
CZ299808B6 (cs) 2008-12-03
CY1106100T1 (el) 2011-06-08
NO20002529L (no) 2000-06-30
DK1308444T3 (da) 2006-09-18
EP1062214A1 (de) 2000-12-27
EP1308444B1 (de) 2006-05-24
DE69834668T2 (de) 2007-01-11

Similar Documents

Publication Publication Date Title
JP4819998B2 (ja) 置換２−（２，６−ジオキソ−３−フルオロピペリジン−３−イル）−イソインドリン類およびＴＮＦαレベルを減少するためのこれらの使用
JP4695259B2 (ja) ２−（２，６−ジオキソピペリジン−３−イル）イソインドリン誘導体、その製剤および炎症性サイトカイン阻害剤としてのその使用
US5874448A (en) Substituted 2-(2,6 dioxo-3-fluoropiperidin-3-yl)-isoindolines and method of reducing TNFα levels
JP4307567B2 (ja) 置換２−（２，６−ジオキソピペリジン−３−イル）−フタルイミド類及び１−オキソイソインドリン類ならびにＴＮＦαレベルの減少方法
US5635517A (en) Method of reducing TNFα levels with amino substituted 2-(2,6-dioxopiperidin-3-yl)-1-oxo-and 1,3-dioxoisoindolines
SK27298A3 (en) Nitrile compounds as inhibitors of tumor necrosis factor alpha, pharmaceutical composition containing the mentioned compounds and their use
EP1062214B1 (de) Substituierte 2-(2,6-dioxo-3-fluoropiperidin-3-yl)-isoindoline und ihre verwendung zur verminderung des tnfa spiegels
AU2002320734B2 (en) Substituted 2-(2,6-dioxo-3-fluoropiperidin-3-yl)-isoindolines and their use to reduce TNFalpha levels
AU2005239663B2 (en) Substituted 2-(2,6-dioxo-3-fluoropiperidin-3-YL)-isoindolines and their use to reduce TNFalpha levels
HK1035363B (en) SUBSTITUTED 2-(2,6-DIOXO-3-FLUOROPIPERIDIN-3-YL)-ISOINDOLINES AND THEIR USE TO REDUCE TNFα LEVELS
HK1091478A (en) Substituted 2-(2,6-dioxo-3-fluoropiperidine-3-yl)-isoindolines and their use to reduce tnf-alpha levels
MXPA00004885A (en) SUBSTITUTED 2-(2,6-DIOXO-3-FLUOROPIPERIDIN-3-YL)-ISOINDOLINES AND THEIR USE TO REDUCE TNF&agr;LEVELS
HK1035180B (en) 2-(2,6-dioxopiperidin-3-yl)isoindoline derivatives, their preparation and their use as inhibitors of inflammatory cytokines
MXPA99010998A (es) 2-(2,6-dioxopiperidin-3-il)ftalamidas y 1-oxoisoindolinas sustituidas y metodo para reducir niveles tnf alfa
JP2015131863A (ja) 置換２−（２，６−ジオキソピペリジン−３−イル）フタルイミド類及び−１−オキソイソインドリン類ならびにＴＮＦαレベルの減少方法
HK1061398A (en) 2-(2,6-dioxopiperidin-3-yl)isoindoline derivatives, their preparation and their use as inhibitors of inflammatory cytokines